These drugs are mainly aimed to lower cholesterol levels by different mechanisms of actions. Mechanism of action Inclisiran is a double-stranded small interfering RNA (siRNA) directed against PCSK9 mRNA. Inclisiran increases LDL-C uptake and lowers LDL-C levels in the circulation, thus decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, inclisiran sodium may cause fetal harm when administered to pregnant patients based on the mechanism of action. Figure 1: Inclisiran’s Mechanism of Action on PCSK9 and Its Role in Lysosomal Degradation as well as LDL Receptor’s Cholesterol Recycling Action. Inclisiran: siRNA conjugated to N-acetylgalactosamine Subcutaneous administration Targeted delivery to hepatocytes Third generation with enhanced stablilisation chemistry Asialoglycoprotein receptor (ASGPR): Highly expressed in hepatocytes only. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing ... Inclisiran increases LDL-C uptake and lowers LDL-C levels in the circulation, thus decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, LEQVIO may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)]. Orphan Drug Status. Mechanism of action. tim tebow endorsement deals. Inclisiran is conjugated to three N-acetylgalactosamine (GalNAc) moieties, designed to target distribution to the liver, which is a significant source of circulating PCSK9. AB - Hypercholesterolemia is a leading cause of cardiovascular morbidity and mortality. Nature (Figure). Tsouka AN, et al. Key technological advances, drug approvals and other important events and setbacks are highlighted. Inclisiran increases LDL-C uptake and lowers LDL-C levels in the circulation, thus decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, LEQVIO may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)]. Novartis Patients with primary hyperoxaluria type 1 produce an excess of oxalate due to a deficiency in the enzyme alanine-glyoxylate aminotransferase. Mechanism of action of inclisiran. Mechanism of Action of Inclisiran in Lipid Lowering Inclisiran vs Repatha (Leqvio vs Evolocumab) for HeFH - Dibesity